Davunetide

N/A

Report date: 2023/03/22 16:42:50
NME

Base Information

Drug NameDavunetide
Drug Alias Name达夫奈肽DavunetidaDavunetidumDavunetide IVNAPVSIPQ +[8] 
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionMicrotubule-associated protein tau inhibitors
TargetsMicrotubule-associated protein tau
Therapy Area/IndicationsSchizophreniaCognitive DysfunctionMacular Degeneration +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesAustralia +[6] 
CombinationsNo
Global Highest StatusPending (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesPaladin Pharma
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesUniversity Of California San FranciscoAllon Therapeutics IncUniversity Of California, Los Angeles
Active IndicationsN/A
Inactive IndicationsSchizophreniaCognitive DysfunctionMacular Degeneration +[5] 

Other Information

ATC CodeN/A
Related LinksKEGG